Sotalol is more effective in maintaining sinus rhythm and treating atrial fibrillation, but is relatively ineffective in reversing the rhythm in the acute phase. Sotalol is a beta-blocker, which can be divided into oral and intravenous formulations, and can be used to treat atrial fibrillation, inhibit atrioventricular conduction, and prolong the period of atrial and atrioventricular node refractoriness. This drug has a high safety profile relative to amiodarone and is a first-line agent for people with atrial fibrillation who have normal left ventricular function and no structural heart disease. Sotalol is also suitable for people who need long-term control of atrial fibrillation with coronary artery disease and left ventricular hypertrophy, and can be taken under medical supervision. However, the drug may cause weakness, dizziness, nausea and other adverse reactions, and should not be used if patients with atrial fibrillation are accompanied by cardiac systolic insufficiency. The drug should not be used by people with bronchial asthma, sinus bradycardia, degree II or degree III AV block, congenital or acquired prolonged QT interval syndrome, or cardiogenic shock. During the period of taking the drug, attention should be paid to monitoring the heart rate and blood pressure changes, the drug may cause bradycardia, dyspnea, dizziness and other adverse reactions, once appeared, it is recommended that patients go to the hospital under the guidance of a professional physician for reasonable diagnosis and treatment.